It has not proved possible to respond to the hon. Member in the time available before Prorogation.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/1559", "label" : {"_value" : "Biography information for Sir James Duddridge"} } , "answeringMemberConstituency" : {"_value" : "Rochford and Southend East"} , "answeringMemberPrinted" : {"_value" : "James Duddridge"} , "dateOfAnswer" : {"_value" : "2019-10-08", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-10-08T15:57:58.427Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "203"} , "answeringDeptShortName" : {"_value" : "Exiting the European Union "} , "answeringDeptSortName" : {"_value" : "Exiting the European Union "} , "date" : {"_value" : "2019-10-01", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "NHS: Drugs"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Exiting the European Union, if she will publish her Department's latest assessment of the effect on the supply of medicines to the UK of the UK leaving the EU without a deal.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1536", "label" : {"_value" : "Biography information for Emily Thornberry"} } , "tablingMemberConstituency" : {"_value" : "Islington South and Finsbury"} , "tablingMemberPrinted" : [{"_value" : "Emily Thornberry"} ], "uin" : "292875"} , {"_about" : "http://data.parliament.uk/resources/1051982", "AnsweringBody" : [{"_value" : "Department for Exiting the European Union "} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1051982/answer", "answerText" : {"_value" : "
DHSC are working closely with life sciences industry and the NHS to make detailed plans to ensure continued access to medicines and devices in all scenarios.<\/p>
We are working with industry to reroute supplies that make use of freight capacity acquired by Government. Medicines and medical products will be prioritised within this additional capacity to ensure that the flow of all these products will continue unimpeded after 29 March 2019. In addition, we are working with pharmaceutical companies to ensure that there is a minimum of six weeks additional supply of medicines in the UK, over and above existing business-as-usual buffer stocks.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4336", "label" : {"_value" : "Biography information for Lord Callanan"} } , "answeringMemberPrinted" : {"_value" : "Lord Callanan"} , "dateOfAnswer" : {"_value" : "2019-02-13", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-02-13T11:52:59.77Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "203"} , "answeringDeptShortName" : {"_value" : "Exiting the European Union "} , "answeringDeptSortName" : {"_value" : "Exiting the European Union "} , "date" : {"_value" : "2019-01-30", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "NHS: Drugs"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask Her Majesty's Government whether they intend to prioritise imports of medicine in their post-Brexit trading arrangements, in the event of a no-deal scenario.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1796", "label" : {"_value" : "Biography information for Lord Taylor of Warwick"} } , "tablingMemberPrinted" : [{"_value" : "Lord Taylor of Warwick"} ], "uin" : "HL13310"} , {"_about" : "http://data.parliament.uk/resources/946902", "AnsweringBody" : [{"_value" : "Department for Exiting the European Union "} ], "answer" : {"_about" : "http://data.parliament.uk/resources/946902/answer", "answerText" : {"_value" : "
The UK is proposing a UK-EU free trade area, underpinned by a common rulebook. For industrial goods, including medicines, it would cover rules that set requirements for placing a product on the market. It would also feature bespoke provisions for human and animal medicines which reflect their unique status, and would be supplemented by continued UK participation in the European Medicines Agency. We look forward to continuing our negotiations with the EU on this issue.<\/p>
In the unlikely event that it is not possible to reach a mutually satisfactory deal with the EU, the Department of Health and Social Care has already set outs its plans in technical notices to ensure that patients can continue to access medicines, including recognising batch-testing carried out in the EU.<\/p>
<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4091", "label" : {"_value" : "Biography information for Mr Robin Walker"} } , "answeringMemberConstituency" : {"_value" : "Worcester"} , "answeringMemberPrinted" : {"_value" : "Mr Robin Walker"} , "dateOfAnswer" : {"_value" : "2018-09-14", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2018-09-14T10:01:10.82Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "203"} , "answeringDeptShortName" : {"_value" : "Exiting the European Union "} , "answeringDeptSortName" : {"_value" : "Exiting the European Union "} , "date" : {"_value" : "2018-07-23", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "NHS: Drugs"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Exiting the European Union, what steps he has taken in negotiations on the UK leaving the EU to promote mutual access to medicines and drugs.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1388", "label" : {"_value" : "Biography information for Lord Dodds of Duncairn"} } , "tablingMemberConstituency" : {"_value" : "Belfast North"} , "tablingMemberPrinted" : [{"_value" : "Nigel Dodds"} ], "uin" : "167159"} , {"_about" : "http://data.parliament.uk/resources/830233", "AnsweringBody" : [{"_value" : "Department for Exiting the European Union "} ], "answer" : {"_about" : "http://data.parliament.uk/resources/830233/answer", "answerText" : {"_value" : "
As we move into the second phase of negotiations we are confident of agreeing a bold and ambitious economic partnership with the EU that is of greater scope than any such existing agreement.<\/p>
<\/strong><\/p> The Government is carrying out an ongoing programme of comprehensive analytical work to define our deep and special partnership with the EU and inform our understanding of how EU exit will affect the UK\u2019s domestic policies and frameworks.<\/p> <\/strong><\/p> We will continue to engage with businesses and industry bodies from all sectors of the economy, and all regions of the UK, in order to inform our negotiations with the EU.<\/p> <\/strong><\/p> Whilst we will not release information that could be prejudicial to our negotiating position, nor provide a running commentary on the Government\u2019s analysis, Ministers have undertaken to provide analysis of the proposed terms of the agreement ahead of a meaningful vote.<\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4091", "label" : {"_value" : "Biography information for Mr Robin Walker"}
}
, "answeringMemberConstituency" : {"_value" : "Worcester"}
, "answeringMemberPrinted" : {"_value" : "Mr Robin Walker"}
, "dateOfAnswer" : {"_value" : "2018-02-01", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : [{"_value" : "124889"}
, {"_value" : "124890"}
, {"_value" : "124891"}
, {"_value" : "124892"}
, {"_value" : "124893"}
, {"_value" : "124895"}
, {"_value" : "124896"}
], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2018-02-01T13:41:13.347Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "203"}
, "answeringDeptShortName" : {"_value" : "Exiting the European Union "}
, "answeringDeptSortName" : {"_value" : "Exiting the European Union "}
, "date" : {"_value" : "2018-01-24", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "NHS: Drugs"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Exiting the European Union, with reference to the speech made by the Secretary of State for International Trade to the American Enterprise Institute of 24 July 2017, what assessment the Government has made of the effect of the increase in non-tariff barriers to trade between 2010 and 2015 on the UK pharmaceutical industry after the UK leaves the EU.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4506", "label" : {"_value" : "Biography information for Antoinette Sandbach"}
}
, "tablingMemberConstituency" : {"_value" : "Eddisbury"}
, "tablingMemberPrinted" : [{"_value" : "Antoinette Sandbach"}
], "uin" : "124894"}
], "itemsPerPage" : 10, "page" : 0, "startIndex" : 1, "totalResults" : 4, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}